West Pharmaceutical Services, Inc.
Eric M. Green
President & CEO
JP Morgan Conference | January10, 2022
Safe Harbor Statement
Cautionary Statement Under the Private Securities Litigation Reform Act of 1995
This presentation and any accompanying management commentary contain "forward- looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about product development and operational performance. Each of these statements is based on preliminary information, and actual results could differ from any preliminary estimates.
We caution investors that the risk factors listed under "Cautionary Statement" in our press releases, as well as those set forth under the caption "Risk Factors" in our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission and as revised or supplemented by our quarterly reports on Form 10-Q, could cause our actual results to differ materially from those estimated or predicted in the forward-looking statements. You should evaluate any statement in light of these important factors. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Non-U.S. GAAP Financial Measures
Certain financial measures included in these presentation materials, or which may be referred to in management's discussion of the Company's results and outlook, have not been calculated in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"), and therefore are referred to as non-U.S. GAAP financial measures. Non-U.S. GAAP financial measures should not be considered in isolation or as an alternative to such measures determined in accordance with U.S. GAAP. Please refer to "Reconciliation of Non-U.S. GAAP Financial Measures" at the end of these materials for more information.
Trademarks
Registered trademarks used in this report are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless noted otherwise. Daikyo Crystal Zenith® and Daikyo® are registered trademarks of Daikyo Seiko, Ltd.
2
OUR PURPOSE
We serve to improve patient lives.
OUR MISSION | OUR VISION | - ENTERPRISE STRATEGIC PLAN - | MAKING AN IMPACT |
We contain and deliver | To be the world leader | EXECUTE | INNOVATE | GROW | TO OUR |
STAKEHOLDERS | |||
injectable therapies that | in the integrated | ||
improve patient lives. | containment and delivery | ||
of injectable medicines. |
OUR CORE VALUES
Passion for Customers
Leadership in Quality
One West Team
3
West is a Global Leader in Containment and Delivery of Injectable Medicines
In 2021, we produced nearly 45 billion components impacting the lives of billions of patients around the world.
VIAL CONTAINMENT | ADMINISTRATION & | DRUG DELIVERY |
& SYRINGE | RECONSTITUTION | & DIAGNOSTIC |
COMPONENTS | DEVICES |
4
Our Journey
STRUCTURED FOR SUCCESS
TRANSFORMATION
GROWTH & EXPANSION | COVID & BEYOND |
COVID-19 PANDEMIC |
2015 | |
Full Review of | 2016 |
Enterprise | |
Strategic Plan |
2017
2018
2019 | 2020 | 2021 |
2022+
- Established Vision, Mission and Values
- Market-Ledapproach & Market Units established
- Moved from Region- Led to Global enterprise
- People Strategy developed
-
Launched first
CR report & ESG 5- year goals - Globalization of Operations & Supply Chain
- Expanded Dublin Facility
- Created Digital Transformation function and Digital Journey began
- Opened Waterford Manufacturing Facility
- Bernard Birkett joins West as CFO
- Silji Abraham joins West as Chief D&T Officer
- Established Bangalore Digital Technology Center, Korea Sales and Scottsdale Development Center
- Increased Equity Stake in Daikyo Seiko Ltd.
- Surpassed ESG 5-year goals
- Established Taiwan Digital Technology Center
- Commercial reorganization / appointed Cindy Reiss-Clark and Chris Ryan
- Kim MacKay joins West as Sr VP General Counsel
- Named to S&P 500 Index and S&P 500 Dividend Aristocrats
- Named 4th in Top 50 ESG companies
BY THE | 2016 |
NUMBERS | |
Employees | 7,269 |
Net Sales | $1.5B |
Market Cap | $5B |
2017
7,505 $1.6B $7B
2018
7,703 $1.7B $7B
201920202021
8,205 | 9,200 | 10,065 |
$1.8B | $2.1B | Through Q3: $2.1B |
$11B | $21B | $30B (as of 01/06/2022) |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
West Pharmaceutical Services Inc. published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 January 2022 14:57:04 UTC.